Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel’s Redhill Biopharma Signs Manufacturing Deal for Potential COVID-19 Treatment
Error: Contact form not found.
by Reuters and Algemeiner Staff
Hospital staff provide medical care for patients at a coronavirus disease (COVID-19) ward, at Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel, Sept. 21, 2020. Photo: Reuters / Ronen Zvulun.
Redhill Biopharma Ltd has signed a manufacturing deal with two companies in Europe and Canada to ramp up production of its coronavirus treatment candidate, the Israeli drugmaker said on Tuesday.
The company said it was expanding manufacturing capabilities for opaganib, its experimental cancer drug for which it intends to apply for emergency use in COVID-19 patients, to meet likely demand after it is approved for such use.
Redhill did not disclose terms of the deal or the name of the manufacturing companies.
Opaganib is being currently tested in patients hospitalized with severe COVID-19 pneumonia in two mid-stage trials — one in the United States and another global study that has received approval in six countries including Italy, Russia, UK and Mexico.
Redhill said it was in discussions with the US government agencies for potential funding to support wider production of opaganib.
